Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–19
Headlines
19
Sources here
6
Companies here
5
Current section Brazil Drug Manufacturers - Specialty & Generic news
Latest

finance.yahoo.com Regulatory and legal

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has …

Main company 🇧🇷 Brazil
Read at finance.yahoo.com
Sharemaestro market context Price below Trend Line 52 weeks -55.1% Z1TS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Provider-linked mention 🇧🇷 Brazil

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia Corporation LQDA reported second-quarter 2026 earnings per share (EPS) of 74 cents, which topped the Zacks Consensus Estimate of 70 cents. In the year-ago quarter, the company reported a loss per share of 49 cents. Total revenues surged to $171.7 million from $8.8 …

U2TH34 mentioned
Sharemaestro market context Price below Trend Line 52 weeks +60.3% · Next-week setup negative 21.9% U2TH34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
nasdaq.com Earnings Main company 🇧🇷 Brazil

Zoetis (ZTS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on …

Z1TS34 main company
Sharemaestro market context Price below Trend Line 52 weeks -55.1% Z1TS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Provider-linked mention 🇧🇷 Brazil

BETA Technologies Inc (BETA) (Q2 2026) Earnings Call Highlights: Revenue Surges 146% as ...

This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue in Q2 2026 was $14.7 million, exceeding guidance and up 146% year-over-year, driven by …

U2TH34 mentioned
Sharemaestro market context Price below Trend Line 52 weeks +60.3% · Next-week setup negative 21.9% U2TH34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Provider-linked mention 🇧🇷 Brazil

Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat

Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. Continue Reading

U2TH34 mentioned
Sharemaestro market context Price below Trend Line 52 weeks +60.3% · Next-week setup negative 21.9% U2TH34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcolepsy type 1, and the company also issued new impairment …

TAKP34 main company
Sharemaestro market context Price above Trend Line 52 weeks +17.2% · Next-week setup negative 39.8% TAKP34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Zoetis (ZTS) Looked Like a Winner. What Went Wrong?

Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …

Z1TS34 main company
Sharemaestro market context Price below Trend Line 52 weeks -55.1% Z1TS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance

ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at …

Z1TS34 mentioned
Sharemaestro market context Price below Trend Line 52 weeks -55.1% Z1TS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Zoetis Q2 Earnings Call Highlights

Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand …

Z1TS34 main company
Sharemaestro market context Price below Trend Line 52 weeks -55.1% Z1TS34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Hypera SA (HYPMY) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic GLP-1 ...

This article first appeared on GuruFocus. Net Revenue: R$2.34 billion, up 8.5% year-over-year. Sell-out Growth: 7.6% growth, driven by skin care, central nervous system, and gut health categories. Gross Margin: 61.8%, an increase of 1.7 percentage points compared to Q2 2025. EBITDA: R$755 million, …

HYPE3 main company
Sharemaestro market context Price below Trend Line 52 weeks -1.8% HYPE3 stored weekly price path from 15 Aug 2025 to 7 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major …

TAKP34 mentioned
Sharemaestro market context Price above Trend Line 52 weeks +17.2% · Next-week setup negative 39.8% TAKP34 stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context